Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Care Bare Rx vs Kin Meds

Care Bare Rx
Graded #43

Higher grade

vs+2.0999999999999943
Kin Meds
Graded #73

Lower grade

The verdict

Care Bare Rx takes it — 75/100 to 72.9/100.

Care Bare Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Oral as well as injectable routes for both molecules plus a brand Ozempic lane, bundled with hair, TRT and sexual health.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueKin Meds +6
68
74
Dose & formulationCare Bare Rx +1
94
93
Clinical oversightEven
74
74
Labs & monitoringCare Bare Rx +9
62
53
FulfillmentCare Bare Rx +6
78
72
Contract termsCare Bare Rx +17
72
55
Care Bare Rx · left barKin Meds · right bar

The numbers

MetricCare Bare RxKin Meds
WeighScore75/10072.9/100
GradeCC
Scorecard rank#43#73
SemaglutideFrom $199/mo (shared weight-loss price)$149/mo (brand Wegovy)
TirzepatideFrom $199/mo (shared weight-loss price)$149/mo (brand Zepbound)
CoverageMulti-stateCoverage not published
Brand-name accessYesYes
Oral / sublingualYesYes
Care Bare Rx

Graded #43 · C

Strengths

  • Oral tirzepatide as well as injectable — rare on this board
  • Brand Ozempic (from $705/mo) and oral Rybelsus beside the compounded line
  • LegitScript certified and HIPAA compliant
  • One platform if you also want hair, TRT, sexual health or NAD+

Where it loses points

  • The advertised "from $199/mo" is one figure shared across all weight-loss treatments — neither molecule priced separately
  • Per-dose pricing is quiz-gated, so a titrated cost cannot be modelled beforehand
  • No named clinicians, founding year or parent company disclosed
  • Compounded medication is not FDA-approved the way brand Ozempic, Wegovy, or Zepbound are
Kin Meds

Graded #73 · C

Strengths

  • Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
  • Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
  • LegitScript verified
  • Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
  • Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health

Where it loses points

  • Legal entity name and state of incorporation not publicly disclosed
  • The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
  • Per-state availability not listed
  • $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
  • Lab work and dose-titration support not clearly described

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard